[Results of a clinical trial of ketoconazole in metastatic prostatic carcinoma].
Ketoconazole action dosed as 400-600 g per day was studied in 12 patients with prostatic metastasizing carcinoma. The decrease in serum testosterone down on castration values was stated in one G1 cancer patient and another two G1, G2 patients approximated to this level. No more than two patients with well differentiated tumour showed the significant decrease in alkaline, acid and prostatic phosphatase down to normal values. No toxic manifestations were stated with only impaired tolerance to the drug in 9 patients from them its administration was discontinued for nausea, vomiting and dysorexia in 2 cases. The favourable clinical action has been signalized in only a half patients. The drug trial showed neither significant decrease in plasmatic testosterone, nor more promising treating results in comparison with current hormonal therapy with stilbenes.
Morávek
P
P
Urologická klinika FN.
Zita
K
K
D000368:Aged; D006801:Humans; D007654:Ketoconazole / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000628:therapy
D007654:Ketoconazole
Výsledky klinického zkousení ketokonazolu u metastazujícího karcinomu prostaty.